FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program

Imagem de Miniatura
Arquivos
art_POYNARD_FibroTest_is_an_independent_predictor_of_virologic_response_2011.PDF (994.49 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
POYNARD, Thierry
MUNTEANU, Mona
COLOMBO, Massimo
BRUIX, Jordi
SCHIFF, Eugene
TERG, Ruben
FLAMM, Steven
MORENO-OTERO, Ricardo
SCHMIDT, Warren
Citação
JOURNAL OF HEPATOLOGY, v.54, n.2, p.227-235, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background & Aims: EPIC-3 is a prospective, international study that has demonstrated the efficacy of PEG-IFN alfa-2b plus weight-based ribavirin in patients with chronic hepatitis C and significant fibrosis who previously failed any interferon-alfa/ribavirin therapy. The aim of the present study was to assess FibroTest (FT), a validated non-invasive marker of fibrosis in treatment-naive patients, as a possible alternative to biopsy as the baseline predictor of subsequent early virologic (EVR) and sustained virologic response (SVR) in previously treated patients. Methods: Of 2312 patients enrolled, 1459 had an available baseline FT, biopsy, and complete data. Uni- (UV) and multi-variable (MV) analyses were performed using FT and biopsy. Results: Baseline characteristics were similar as in the overall population; METAVIR stage: 28% F2, 29% F3, and 43% F4, previous relapsers 29%, previous PEG-IFN regimen 41%, high baseline viral load (BVL) 64%. 506 patients (35%) had undetectable HCV-RNA at TW12 (TW12neg), with 58% achieving SVR. The accuracy of FT was similar to that in naive patients: AUROC curve for the diagnosis of F4 vs F2 = 0.80 (p<0.00001). Five baseline factors were associated (p<0.001) with SVR in UV and MV analyses (odds ratio: UV/MV): fibrosis stage estimated using FT (4.5/5.9) or biopsy (1.5/1.6), genotype 2/3 (4.5/5.1), BVL (1.5/1.3), prior relapse (1.6/1.6), previous treatment with non-PEG-IFN (2.6/2.0). These same factors were associated (p <= 0.001) with EVR. Among patients TW12neg, two independent factors remained highly predictive of SVR by MV analysis (p <= 0.001): genotype 2/3 (odds ratio = 2.9), fibrosis estimated with FT (4.3) or by biopsy (1.5). Conclusions: FibroTest at baseline is a possible non-invasive alternative to biopsy for the prediction of EVR at 12 weeks and SVR, in patients with previous failures and advanced fibrosis, retreated with PEG-IFN alfa-2b and ribavirin.
Palavras-chave
Hepatitis C, Non-responder, Relapser, Cirrhosis, Fibrosis, Biomarkers, Treatment failure, Early virologic response
URI
https://observatorio.fm.usp.br/handle/OPI/23031
Referências
  1. Afdhal NH, 2008, J HEPATOL, V48, pS4, DOI 10.1016/S0168-8278(08)60005-7
  2. Di Bisceglie AM, 2008, NEW ENGL J MED, V359, P2429, DOI 10.1056/NEJMoa0707615
  3. Poynard T, 2004, CLIN CHEM, V50, P1344, DOI 10.1373/clinchem.2004.032227
  4. Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
  5. Poynard T, 2007, CLIN CHEM, V53, P1615, DOI 10.1373/clinchem.2007.085795
  6. [Anonymous], 2002, NIH CONSENS STATE SC, V19, P1
  7. Naveau S, 2009, HEPATOLOGY, V49, P97, DOI 10.1002/hep.22576
  8. Poynard T, 2009, NEW ENGL J MED, V360, P1152
  9. Poynard T, 2007, ALIMENT PHARM THERAP, V25, P733, DOI 10.1111/j.1365-2036.2007.03252.x
  10. Poynard T, 2002, J VIRAL HEPATITIS, V9, P128, DOI 10.1046/j.1365-2893.2002.00341.x
  11. Fontaine H, 2007, GASTROEN CLIN BIOL, V31, P504, DOI 10.1016/S0399-8320(07)89420-6
  12. Poynard T, 2003, HEPATOLOGY, V38, P481, DOI 10.1053/jhep.2003.50319
  13. Lambert J, 2008, CLIN CHEM, V54, P1372, DOI 10.1373/clinchem.2007.097923
  14. Poynard T, 2003, HEPATOLOGY, V38, P75, DOI 10.1053/jhep.2003.50267
  15. Halfon P, 2008, GASTROEN CLIN BIOL, V32, P22, DOI 10.1016/S0399-8320(08)73991-5
  16. Imbert-Bismut F, 2004, CLIN CHEM LAB MED, V42, P323, DOI 10.1515/CCLM.2004.058
  17. Veldt BJ, 2007, ANN INTERN MED, V147, P677
  18. Poynard T, 2000, HEPATOLOGY, V31, P211, DOI 10.1002/hep.510310131
  19. Poynard T, 2009, GASTROENTEROLOGY, V136, P1618, DOI 10.1053/j.gastro.2009.01.039
  20. Manning DS, 2008, GASTROENTEROLOGY, V134, P1670, DOI 10.1053/j.gastro.2008.03.001
  21. Ngo Y, 2006, CLIN CHEM, V52, P1887, DOI 10.1373/clinchem.2006.070961
  22. Poynard T, 2010, GASTROEN CLIN BIOL, V34, P388, DOI 10.1016/j.gcb.2010.05.001
  23. Bedossa P, 2003, HEPATOLOGY, V38, p337A
  24. Brissot Pierre, 2006, Hematology Am Soc Hematol Educ Program, P36
  25. Bruix J, 2009, J HEPATOL, V50, pS22
  26. d'Arondel C, 2006, J VIRAL HEPATITIS, V13, P182, DOI 10.1111/j.1365-2893.2005.00668.x
  27. DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
  28. Hintze JL, 2007, NCSS 2007 USER GUIDE
  29. Imbert-Bismut F, 2005, ANN BIOL CLIN-PARIS, V63, P305
  30. La Haute Autorite de Sante (HAS) in France, HAS REC MAN CHRON HE
  31. Ngo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002573
  32. Patel K, 2009, J VIRAL HEPATITIS, V16, P178, DOI 10.1111/j.1365-2893.2008.01062.x
  33. Poynard T, 2004, COMP HEPATOL, V3, P8, DOI 10.1186/1476-5926-3-8
  34. Poynard Thierry, 2005, Comp Hepatol, V4, P10, DOI 10.1186/1476-5926-4-10
  35. Poynard T, 2008, GASTROEN CLIN BIOL, V32, P8, DOI 10.1016/S0399-8320(08)73990-3
  36. ZHOU X, 2002, STAT METHODS DIAGNOS, P235

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07